Back to top

Analyst Blog

We recently reiterated our Neutral recommendation on biopharmaceutical company, Geron Corporation (GERN - Analyst Report), which carries a Zacks #3 Rank (short-term Hold rating).

Geron focuses on the development of first-in-class therapeutic products for the treatment of cancer. The company currently has two candidates in its pipeline: imetelstat (GRN163L) and GRN1005. Imetelstat is currently in four phase II studies: non-small cell lung cancer, essential thrombocythemia, multiple myeloma, and breast cancer.

GRN1005, which became a part of Geron’s pipeline following its agreement with Angiochem, Inc., is currently in two phase II studies, which are being conducted in patients with brain metastases arising from non-small cell lung cancer (GRABM-L) and breast cancer (GRABM-B). Top-line data from these studies should be out by the end of the second quarter of 2013.

In mid-November 2011, Geron, an erstwhile leader in stem cell research, announced its intention to exit the stem cell therapy market. Geron’s decision was based on a strategic review. Given the current economic environment of capital scarcity and uncertainty, Geron decided to focus on its oncology program which has several important milestones coming up over the next 20 months.

While the company’s decision to focus on oncology should deliver in the long-term, we expect the stock to remain range-bound in the near term given the lack of catalysts. Results on the oncology candidates should start coming out in late 2012 – we prefer to remain on the sidelines until we see data on these candidates.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
BANCO DO BR… BDORY 14.74 +5.66%
AIR INDUSTR… AIRI 9.99 +4.15%
EQT MIDSTRE… EQM 98.14 +3.38%
WEATHERFORD… WFT 23.64 +3.10%